Cancer Advisor

White Paper · Integrative Oncology · June 2026 ✎ OneDayMD Editorial Team  Last Updated: June 21, 2026   Medically Reviewed by: OneDayMD Editorial Team  DOI-equivalent: onedaymd.com/fenbendazole-cancer-protocol-2026 Abstract Background: Cancer remains the second leading cause of death globally. Advanced-stage disease carries poor prognosis, and a significant proportion of patients either fail conventional therapy or seek adjunctive options. Over the past decade, the repurposed antiparasitic agents fenbendazole, ivermectin, and mebendazole have attracted increasing attention for potential anti-neoplastic activity based on preclinical and emerging clinical data. Objective: To synthesise (1) a systematic case-series compilation of 760+ patient-reported outcomes across 31 cancer subtypes involving antiparasitic repurposed drugs; (2) an evidence-based 7-layer Metabolic Cancer Frame...

Abstract A 2026 study published in JAMA Network Open has reignited debate over the use of ivermectin and benzimidazole drugs—including fenbendazole and mebendazole—among cancer patients. The study analyzed approximately 68.4 million patient records and documented a substantial increase in prescriptions following a widely viewed discussion on The Joe Rogan Experience featuring actor Mel Gibson. While supporters view the publication as validation that these drugs are being increasingly used in real-world cancer settings, critics emphasize that the study evaluated prescribing behavior rather than clinical outcomes. This distinction is critical. The study did not assess tumor response, progression-free survival, overall survival, or quality-of-life outcomes. This article examines what the study found, what it did not find, and why the publication has become a focal point in the ongoing debate surrounding drug repurposing in oncology. Introduction A 2026 study published in JAMA Network Ope...